FDA Lifts Clinical Hold on GH001, Paving Way for Global Phase 3 in Treatment-Resistant Depression

summarizeSummary

GH Research announced the FDA has lifted the clinical hold on its lead drug candidate, GH001, for treatment-resistant depression, clearing the path for global Phase 3 trials to begin in 2026.

check_boxKey Events

• FDA Clinical Hold Lifted

  The U.S. Food and Drug Administration (FDA) has removed the clinical hold on GH001's Investigational New Drug (IND) application.

• Path to Global Phase 3

  This clearance enables U.S. subject enrollment and allows GH Research to proceed with its global pivotal Phase 3 program for GH001 in treatment-resistant depression (TRD), targeted for initiation in 2026.

• Strong Phase 2b Data

  Previously reported Phase 2b trial (GH001-TRD-201) showed GH001 met its primary endpoint with a -15.5 point placebo-adjusted MADRS reduction on Day 8 (p<0.0001) and achieved 57.5% ultra-rapid remission on Day 8.

• Favorable Profile

  GH001 demonstrated 73% remission at 6 months with infrequent dosing, a short psychoactive experience (median ~11 minutes), no required psychotherapy, and a favorable safety profile with no serious treatment-related adverse events.

auto_awesomeAnalysis

The U.S. FDA's decision to lift the clinical hold on GH Research's lead candidate, GH001, is a significant positive development. This regulatory clearance removes a major hurdle, enabling U.S. patient enrollment and allowing the company to advance GH001 into a global pivotal Phase 3 program for treatment-resistant depression (TRD) in 2026. The company's previously reported Phase 2b data for GH001 demonstrated strong efficacy, ultra-rapid remission, and a favorable safety profile, which, if replicated in Phase 3, could position GH001 as a highly competitive and potentially practice-changing treatment option in the TRD market. Investors should monitor the initiation and progress of the Phase 3 trials.